New GlaxoSmithKline lung drug nabs thumbs-up from FDA experts

An FDA advisory panel gave an approval stamp to GlaxoSmithKline's ($GSK) new lung drug, Breo. The agency advisers weren't unanimous in backing GSK's follow-up to now-off-patent Advair, however; some expressed reservations about Breo's ability to reduce exacerbations in COPD patients and about its safety. Report